Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Igor Odintsov, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Iyer SR, Odintsov I, Schoenfeld AJ, Siau E, Mattar MS, de Stanchina E, Khodos I, Drilon A, Riely GJ, Ladanyi M, Somwar R, Davare MA. MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. Mol Cancer Res. 2022 05 04; 20(5):722-734. PMID: 35149545; PMCID: PMC9081178.
    Citations:    Fields:    Translation:Humans
  2. Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, Wasserman E, de Stanchina E, O'Reilly EM, Ladanyi M, Drilon A, Somwar R. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 05 02; 12(5):1233-1247. PMID: 35135829; PMCID: PMC9394398.
    Citations: 2     Fields:    Translation:HumansCells
  3. Choo F, Odintsov I, Nusser K, Nicholson K, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA. Corrigendum: Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harb Mol Case Stud. 2022 Apr; 8(3). PMID: 35483883; PMCID: PMC9059788.
    Citations:    Fields:    
  4. Odintsov I, Ortiz MV, Khodos I, Mattar MS, Lui AJW, Kohsaka S, de Stanchina E, Bender JLG, Ladanyi M, Somwar R. CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. Cancer Res. 2022 03 15; 82(6):1110-1127. PMID: 35074756; PMCID: PMC8930606.
    Citations:    Fields:    Translation:HumansCells
  5. Choo F, Odintsov I, Nusser K, Nicholson KS, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA. Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harb Mol Case Stud. 2022 01; 8(1). PMID: 35012940; PMCID: PMC8744497.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  6. Smith RS, Odintsov I, Liu Z, Lui AJ, Hayashi T, Vojnic M, Suehara Y, Delasos L, Mattar MS, Hmeljak J, Ramirez HA, Shaw M, Bui G, Hartono AB, Gladstone E, Kunte S, Magnan H, Khodos I, De Stanchina E, La Quaglia MP, Yao J, Laé M, Lee SB, Spraggon L, Pratilas CA, Ladanyi M, Somwar R. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. Dis Model Mech. 2022 01 01; 15(1). PMID: 34841430; PMCID: PMC8807576.
    Citations:    Fields:    Translation:HumansAnimals
  7. Krsková L, Odintsov I, Fabián O, Hroudová P, Mrhalová M. Determination of biological behavior of solitary fibrous tumors: correlation of expression of Ki-67, TPX2 and TERT mRNA subunit level and NAB2-STAT6 fusion compared to morphological aspects of SFTs. Neoplasma. 2022 Jan; 69(1):28-35. PMID: 34818026.
    Citations:    Fields:    Translation:Humans
  8. Odintsov I, Mattar MS, Lui AJW, Offin M, Kurzatkowski C, Delasos L, Khodos I, Asher M, Daly RM, Rekhtman N, de Stanchina E, Ganji G, Ladanyi M, Somwar R. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. J Thorac Oncol. 2021 07; 16(7):1149-1165. PMID: 33839363; PMCID: PMC9261529.
    Citations: 3     Fields:    Translation:HumansCells
  9. Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, Kurth RI, Sisso EM, Vojnic M, Khodos I, Mattar MS, de Stanchina E, Leland SM, Ladanyi M, Somwar R. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clin Cancer Res. 2021 06 01; 27(11):3154-3166. PMID: 33824166; PMCID: PMC8172458.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  10. Odintsov I, Somwar R, Ladanyi M, Drilon A. ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development. JCO Oncol Pract. 2021 01; 17(1):15-16. PMID: 33434449.
    Citations:    Fields:    Translation:Humans
  11. Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Commun Biol. 2020 12 16; 3(1):776. PMID: 33328556.
    Citations: 9     Translation:HumansAnimalsCells
  12. Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, Stanchina E, Ladanyi M, Somwar R. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation. Dis Model Mech. 2020 Dec 14. PMID: 33318047.
    Citations: 3     Fields:    
  13. Ogura K, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, Bowman AS, Mattar MS, Khodos I, de Stanchina E, Jungbluth A, Asher M, Odintsov I, Hartono AB, LaQuaglia MP, Slotkin E, Pratilas CA, Lee SB, Spraggon L, Ladanyi M. Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2021 02 15; 27(4):1184-1194. PMID: 33229458; PMCID: PMC8212565.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  14. Vodicka P, Krskova L, Odintsov I, Krizova L, Sedlackova E, Schutzner J, Zamecnik J. Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas. Oncol Lett. 2020 Mar; 19(3):2413-2421. PMID: 32194741; PMCID: PMC7039126.
    Citations: 2     
  15. Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M. Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. JCO Precis Oncol. 2019; 3. PMID: 31157314; PMCID: PMC6541452.
    Citations: 13     Fields:    
  16. Odintsov I, Somwar R, Davare MA. A blast from the past: ROS1 on the brain. Oncotarget. 2019 Mar 01; 10(18):1664-1666. PMID: 30899438; PMCID: PMC6422201.
    Citations: 1     Fields:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Odintsov's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (72)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.